- published: 07 Nov 2016
- views: 116
Create your page here
-
remove the playlistGilead Sciences
- remove the playlistGilead Sciences
back to playlist
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s work in liver diseases includes a portfolio of products and a pipeline of investigational drugs in viral hepatitis (hepatitis B and hepatitis C), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Gilead’s partnerships in science, academia, business and local communities enhance its ability to develop innovative medicines and deliver them to people as efficiently as possible.
http://www.gilead.com
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth.
This podcast was recorded on May 4, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 07 May 2016
- views: 830
Benzinga Newsdesk discussed reactions to reduced pharma stock.
For realtime updates follow @benzinga on Twitter or visit www.benzinga.com.
- published: 08 Feb 2017
- views: 360
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $103 billion, a price to earnings ratio of 6.86 and a dividend yield of 2.41 per cent. Guest Gary Booysen from Rand Swiss and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
- published: 01 Sep 2016
- views: 344
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013:
Meet John F. Milligan, President and Chief Operating Officer, Gilead Sciences
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
- published: 26 Feb 2013
- views: 5012
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable patient population kicks in.
This podcast was recorded on May 4, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 07 May 2016
- views: 365
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter.com/AlexanderFB89
Disclaimer: All information is shared for educational purposes only and are not solicitations or recommendations to buy or sell securities. Each person must conduct their own research, analysis, and risk-assessment before every trade. None of this information is to be construed as investment and trading advice. No one at Alex Charting is a registered investment adviser, broker dealer, or in any other way qualified to give financial advice. Any use you make of our content is at your own risk and your own responsibility. You hereby agree that you shall not make any financial, investment, legal and/or other decision based in whole or in part on anything contained in our Website or Services. There is no guarantee that the information on www.alexcharting.com (or related sites) is correct, complete, or current. Further, you accept that www.alexcharting.com could experience technical problems rendering parts or all of the website unavailable at any time. www.alexcharting.com is protected by McAfee Antivirus, but there is no guarantee that its free from viruses. There may be ads or sponsorship on www.alexcharting.com, and you accept that Alex Charting is not in any way responsible for your use of such content. You accept that Alex Charting does not offer refunds for any of its products or services. Owners, employees, agents or representatives of Alex Charting may have interests or positions in securities of the entities profiled herein. Specifically, such parties may buy or sell positions, and may or may not follow the information provided on www.alexcharting.com (or related sites). Some or all of the positions may have been acquired prior to the publication of such information on www.alexcharting.com (or related sites), and such positions may increase or decrease at any time. All trading involve serious risks, and you can lose your entire investment. Additionally, you may lose more than your entire investment if you are trading futures or trading on margin.
- published: 24 Mar 2017
- views: 74
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $97.88 billion, a price to earnings ratio of 7.28 and a dividend yield of 2.40 per cent. Guest Wayne McCurrie Williams from Ashburton and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
- published: 11 Nov 2016
- views: 4
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com .
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
- published: 07 Feb 2017
- views: 96
Gilead Sciences
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. In 2006, Gilead acquired two companies which were developing drugs to treat patients with pulmonary diseases.
The company's current commercially available products include Atripla, Complera, Emtriva, Viread, Tybost, Vitekta, Truvada, Stribild, Harvoni, Hepsera, Sovaldi, Zydelig, Letairis, Lexiscan, Ranexa, Cayston, Tamiflu, AmBisome, and Macugen.
Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2015, the company had approximately 7,900 full-time employees. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
The company's name and logo refer to the Balm of Gilead, inspired by a 1965 play by Langford Wilson featuring the underworld adventures of the patrons of the namesake cafe.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/Gilead_Sciences
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
5:31Gilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences, Inc: A Commitment To InnovationGilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s work in liver diseases includes a portfolio of products and a pipeline of investigational drugs in viral hepatitis (hepatitis B and hepatitis C), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Gilead’s partnerships in science, academia, business and local communities enhance its ability to develop innovative medicines and deliver them to people as efficiently as possible. http://www.gilead.com -
2:45What's Gilead Sciences Doing With All That Cash?
What's Gilead Sciences Doing With All That Cash?What's Gilead Sciences Doing With All That Cash?
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth. This podcast was recorded on May 4, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool -
3:37Gilead's 2017 Guidance Sank Shares To A New Bottom
Gilead's 2017 Guidance Sank Shares To A New BottomGilead's 2017 Guidance Sank Shares To A New Bottom
Benzinga Newsdesk discussed reactions to reduced pharma stock. For realtime updates follow @benzinga on Twitter or visit www.benzinga.com. -
3:06Gilead Sciences - Hot or Not
Gilead Sciences - Hot or NotGilead Sciences - Hot or Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $103 billion, a price to earnings ratio of 6.86 and a dividend yield of 2.41 per cent. Guest Gary Booysen from Rand Swiss and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not. -
0:33Stock to Watch in ’17: Gilead Sciences
Stock to Watch in ’17: Gilead Sciences -
26:37Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead SciencesFireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013: Meet John F. Milligan, President and Chief Operating Officer, Gilead Sciences Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008. Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University. Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco. -
7:07What's Behind Gilead Sciences Drop In Hepatitis C Sales?
What's Behind Gilead Sciences Drop In Hepatitis C Sales?What's Behind Gilead Sciences Drop In Hepatitis C Sales?
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable patient population kicks in. This podcast was recorded on May 4, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool -
13:30Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad PortfolioGilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter.com/AlexanderFB89 Disclaimer: All information is shared for educational purposes only and are not solicitations or recommendations to buy or sell securities. Each person must conduct their own research, analysis, and risk-assessment before every trade. None of this information is to be construed as investment and trading advice. No one at Alex Charting is a registered investment adviser, broker dealer, or in any other way qualified to give financial advice. Any use you make of our content is at your own risk and your own responsibility. You hereby agree that you shall not make any financial, investment, legal and/or other decision based in whole or in part on anything contained in our Website or Services. There is no guarantee that the information on www.alexcharting.com (or related sites) is correct, complete, or current. Further, you accept that www.alexcharting.com could experience technical problems rendering parts or all of the website unavailable at any time. www.alexcharting.com is protected by McAfee Antivirus, but there is no guarantee that its free from viruses. There may be ads or sponsorship on www.alexcharting.com, and you accept that Alex Charting is not in any way responsible for your use of such content. You accept that Alex Charting does not offer refunds for any of its products or services. Owners, employees, agents or representatives of Alex Charting may have interests or positions in securities of the entities profiled herein. Specifically, such parties may buy or sell positions, and may or may not follow the information provided on www.alexcharting.com (or related sites). Some or all of the positions may have been acquired prior to the publication of such information on www.alexcharting.com (or related sites), and such positions may increase or decrease at any time. All trading involve serious risks, and you can lose your entire investment. Additionally, you may lose more than your entire investment if you are trading futures or trading on margin. -
4:14Gilead Sciences - Hot or Not
Gilead Sciences - Hot or NotGilead Sciences - Hot or Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $97.88 billion, a price to earnings ratio of 7.28 and a dividend yield of 2.40 per cent. Guest Wayne McCurrie Williams from Ashburton and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not. -
2:01Gilead Sciences
Gilead SciencesGilead Sciences
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com . Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: company@whyinvestin.com
-
Gilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s work in liver diseases includes a portfolio of products and a pipeline of investigational drugs in viral hepatitis (hepatitis B and hepatitis C), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Gilead’s partnerships in science, academia, business and local communities enhance its ability to develop innovative medicines and deliver them to people as efficiently as possible. http://www.gilead.com
published: 07 Nov 2016 -
What's Gilead Sciences Doing With All That Cash?
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth. This podcast was recorded on May 4, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook...
published: 07 May 2016 -
Gilead's 2017 Guidance Sank Shares To A New Bottom
Benzinga Newsdesk discussed reactions to reduced pharma stock. For realtime updates follow @benzinga on Twitter or visit www.benzinga.com.
published: 08 Feb 2017 -
Gilead Sciences - Hot or Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $103 billion, a price to earnings ratio of 6.86 and a dividend yield of 2.41 per cent. Guest Gary Booysen from Rand Swiss and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
published: 01 Sep 2016 -
Stock to Watch in ’17: Gilead Sciences
Stock to Watch in ’17: Gilead Sciences
published: 16 Dec 2016 -
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013: Meet John F. Milligan, President and Chief Operating Officer, Gilead Sciences Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008. Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined...
published: 26 Feb 2013 -
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable patient population kicks in. This podcast was recorded on May 4, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: http...
published: 07 May 2016 -
Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter.com/AlexanderFB89 Disclaimer: All information is shared for educational purposes only and are not solicitations or recommendations to buy or sell securities. Each person must conduct their own research, analysis, and risk-assessment before every trade. None of this information is to be construed as investment and trading advice. No one at Alex Charting is a registered investment adviser, broker dealer, or in any other way qualified to give financial advice. Any use you make of our content is at your own risk and your own responsibility. You hereby agree that you shall not make any financial, investment, legal and/or other decision based in whole or in part on anything contained in our Website or Servi...
published: 24 Mar 2017 -
Gilead Sciences - Hot or Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $97.88 billion, a price to earnings ratio of 7.28 and a dividend yield of 2.40 per cent. Guest Wayne McCurrie Williams from Ashburton and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
published: 11 Nov 2016 -
Gilead Sciences
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER ...
published: 07 Feb 2017
Gilead Sciences, Inc: A Commitment To Innovation
- Order: Reorder
- Duration: 5:31
- Updated: 07 Nov 2016
- views: 116
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical n...
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s work in liver diseases includes a portfolio of products and a pipeline of investigational drugs in viral hepatitis (hepatitis B and hepatitis C), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Gilead’s partnerships in science, academia, business and local communities enhance its ability to develop innovative medicines and deliver them to people as efficiently as possible.
http://www.gilead.com
https://wn.com/Gilead_Sciences,_Inc_A_Commitment_To_Innovation
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s work in liver diseases includes a portfolio of products and a pipeline of investigational drugs in viral hepatitis (hepatitis B and hepatitis C), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Gilead’s partnerships in science, academia, business and local communities enhance its ability to develop innovative medicines and deliver them to people as efficiently as possible.
http://www.gilead.com
- published: 07 Nov 2016
- views: 116
What's Gilead Sciences Doing With All That Cash?
- Order: Reorder
- Duration: 2:45
- Updated: 07 May 2016
- views: 830
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth.
This podcast was recorded on May 4, 2016.
Imagine owning A...
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth.
This podcast was recorded on May 4, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
https://wn.com/What's_Gilead_Sciences_Doing_With_All_That_Cash
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future growth.
This podcast was recorded on May 4, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 07 May 2016
- views: 830
Gilead's 2017 Guidance Sank Shares To A New Bottom
- Order: Reorder
- Duration: 3:37
- Updated: 08 Feb 2017
- views: 360
Benzinga Newsdesk discussed reactions to reduced pharma stock.
For realtime updates follow @benzinga on Twitter or visit www.benzinga.com.
Benzinga Newsdesk discussed reactions to reduced pharma stock.
For realtime updates follow @benzinga on Twitter or visit www.benzinga.com.
https://wn.com/Gilead's_2017_Guidance_Sank_Shares_To_A_New_Bottom
Benzinga Newsdesk discussed reactions to reduced pharma stock.
For realtime updates follow @benzinga on Twitter or visit www.benzinga.com.
- published: 08 Feb 2017
- views: 360
Gilead Sciences - Hot or Not
- Order: Reorder
- Duration: 3:06
- Updated: 01 Sep 2016
- views: 344
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $103 billion, a price to earnings ratio of 6.86 ...
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $103 billion, a price to earnings ratio of 6.86 and a dividend yield of 2.41 per cent. Guest Gary Booysen from Rand Swiss and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
https://wn.com/Gilead_Sciences_Hot_Or_Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $103 billion, a price to earnings ratio of 6.86 and a dividend yield of 2.41 per cent. Guest Gary Booysen from Rand Swiss and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
- published: 01 Sep 2016
- views: 344
Stock to Watch in ’17: Gilead Sciences
- Order: Reorder
- Duration: 0:33
- Updated: 16 Dec 2016
- views: 72
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
- Order: Reorder
- Duration: 26:37
- Updated: 26 Feb 2013
- views: 5012
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013:
Meet John F. Milligan, President and Chief ...
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013:
Meet John F. Milligan, President and Chief Operating Officer, Gilead Sciences
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
https://wn.com/Fireside_Chat_With_John_F._Milligan,_Phd,_President_And_Chief_Operating_Officer,_Gilead_Sciences
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013:
Meet John F. Milligan, President and Chief Operating Officer, Gilead Sciences
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. Dr. Milligan is a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
- published: 26 Feb 2013
- views: 5012
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
- Order: Reorder
- Duration: 7:07
- Updated: 07 May 2016
- views: 365
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable patient population kicks in.
This podcast was recorded on May 4, 2016.
...
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable patient population kicks in.
This podcast was recorded on May 4, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
https://wn.com/What's_Behind_Gilead_Sciences_Drop_In_Hepatitis_C_Sales
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable patient population kicks in.
This podcast was recorded on May 4, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 07 May 2016
- views: 365
Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
- Order: Reorder
- Duration: 13:30
- Updated: 24 Mar 2017
- views: 74
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter.com/AlexanderFB89
Disclaimer: All information is shared for educationa...
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter.com/AlexanderFB89
Disclaimer: All information is shared for educational purposes only and are not solicitations or recommendations to buy or sell securities. Each person must conduct their own research, analysis, and risk-assessment before every trade. None of this information is to be construed as investment and trading advice. No one at Alex Charting is a registered investment adviser, broker dealer, or in any other way qualified to give financial advice. Any use you make of our content is at your own risk and your own responsibility. You hereby agree that you shall not make any financial, investment, legal and/or other decision based in whole or in part on anything contained in our Website or Services. There is no guarantee that the information on www.alexcharting.com (or related sites) is correct, complete, or current. Further, you accept that www.alexcharting.com could experience technical problems rendering parts or all of the website unavailable at any time. www.alexcharting.com is protected by McAfee Antivirus, but there is no guarantee that its free from viruses. There may be ads or sponsorship on www.alexcharting.com, and you accept that Alex Charting is not in any way responsible for your use of such content. You accept that Alex Charting does not offer refunds for any of its products or services. Owners, employees, agents or representatives of Alex Charting may have interests or positions in securities of the entities profiled herein. Specifically, such parties may buy or sell positions, and may or may not follow the information provided on www.alexcharting.com (or related sites). Some or all of the positions may have been acquired prior to the publication of such information on www.alexcharting.com (or related sites), and such positions may increase or decrease at any time. All trading involve serious risks, and you can lose your entire investment. Additionally, you may lose more than your entire investment if you are trading futures or trading on margin.
https://wn.com/Gilead_Sciences_(Gild)_Large_Cap_Biopharmaceutical_Firm_With_Broad_Portfolio
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter.com/AlexanderFB89
Disclaimer: All information is shared for educational purposes only and are not solicitations or recommendations to buy or sell securities. Each person must conduct their own research, analysis, and risk-assessment before every trade. None of this information is to be construed as investment and trading advice. No one at Alex Charting is a registered investment adviser, broker dealer, or in any other way qualified to give financial advice. Any use you make of our content is at your own risk and your own responsibility. You hereby agree that you shall not make any financial, investment, legal and/or other decision based in whole or in part on anything contained in our Website or Services. There is no guarantee that the information on www.alexcharting.com (or related sites) is correct, complete, or current. Further, you accept that www.alexcharting.com could experience technical problems rendering parts or all of the website unavailable at any time. www.alexcharting.com is protected by McAfee Antivirus, but there is no guarantee that its free from viruses. There may be ads or sponsorship on www.alexcharting.com, and you accept that Alex Charting is not in any way responsible for your use of such content. You accept that Alex Charting does not offer refunds for any of its products or services. Owners, employees, agents or representatives of Alex Charting may have interests or positions in securities of the entities profiled herein. Specifically, such parties may buy or sell positions, and may or may not follow the information provided on www.alexcharting.com (or related sites). Some or all of the positions may have been acquired prior to the publication of such information on www.alexcharting.com (or related sites), and such positions may increase or decrease at any time. All trading involve serious risks, and you can lose your entire investment. Additionally, you may lose more than your entire investment if you are trading futures or trading on margin.
- published: 24 Mar 2017
- views: 74
Gilead Sciences - Hot or Not
- Order: Reorder
- Duration: 4:14
- Updated: 11 Nov 2016
- views: 4
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $97.88 billion, a price to earnings ratio of 7.2...
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $97.88 billion, a price to earnings ratio of 7.28 and a dividend yield of 2.40 per cent. Guest Wayne McCurrie Williams from Ashburton and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
https://wn.com/Gilead_Sciences_Hot_Or_Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. It has a market cap of $97.88 billion, a price to earnings ratio of 7.28 and a dividend yield of 2.40 per cent. Guest Wayne McCurrie Williams from Ashburton and resident expert Paul Theron from Vestact decide whether Gilead Sciences is hot or not.
- published: 11 Nov 2016
- views: 4
Gilead Sciences
- Order: Reorder
- Duration: 2:01
- Updated: 07 Feb 2017
- views: 96
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global secur...
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com .
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
https://wn.com/Gilead_Sciences
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com .
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
- published: 07 Feb 2017
- views: 96
fullscreen slideshow
- Playlist
- Chat
fullscreen slideshow
- Playlist
- Chat
5:31
Gilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develo...
published: 07 Nov 2016
Gilead Sciences, Inc: A Commitment To Innovation
Gilead Sciences, Inc: A Commitment To Innovation
- Report rights infringement
- published: 07 Nov 2016
- views: 116
2:45
What's Gilead Sciences Doing With All That Cash?
A $21 billion cash stockpile gives management plenty of financial firepower to fuel future...
published: 07 May 2016
What's Gilead Sciences Doing With All That Cash?
What's Gilead Sciences Doing With All That Cash?
- Report rights infringement
- published: 07 May 2016
- views: 830
3:37
Gilead's 2017 Guidance Sank Shares To A New Bottom
Benzinga Newsdesk discussed reactions to reduced pharma stock.
For realtime updates foll...
published: 08 Feb 2017
Gilead's 2017 Guidance Sank Shares To A New Bottom
Gilead's 2017 Guidance Sank Shares To A New Bottom
- Report rights infringement
- published: 08 Feb 2017
- views: 360
3:06
Gilead Sciences - Hot or Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. I...
published: 01 Sep 2016
Gilead Sciences - Hot or Not
Gilead Sciences - Hot or Not
- Report rights infringement
- published: 01 Sep 2016
- views: 344
0:33
Stock to Watch in ’17: Gilead Sciences
Stock to Watch in ’17: Gilead Sciences
published: 16 Dec 2016
Stock to Watch in ’17: Gilead Sciences
Stock to Watch in ’17: Gilead Sciences
- Report rights infringement
- published: 16 Dec 2016
- views: 72
26:37
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New Yor...
published: 26 Feb 2013
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
Fireside Chat With John F. Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
- Report rights infringement
- published: 26 Feb 2013
- views: 5012
7:07
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
Gilead Sciences' Harvoni sales are dipping, as cost cutting to expand the addressable pati...
published: 07 May 2016
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
What's Behind Gilead Sciences Drop In Hepatitis C Sales?
- Report rights infringement
- published: 07 May 2016
- views: 365
13:30
Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
Facebook: https://www.facebook.com/AlexCharting-979365105507508/ Twitter: https://twitter....
published: 24 Mar 2017
Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
Gilead Sciences (GILD): Large-cap Biopharmaceutical Firm with Broad Portfolio
- Report rights infringement
- published: 24 Mar 2017
- views: 74
4:14
Gilead Sciences - Hot or Not
Gilead Sciences is a pharma company which has a focus on drugs for HIV and Hepatitis-C. I...
published: 11 Nov 2016
Gilead Sciences - Hot or Not
Gilead Sciences - Hot or Not
- Report rights infringement
- published: 11 Nov 2016
- views: 4
2:01
Gilead Sciences
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you...
published: 07 Feb 2017
Gilead Sciences
Gilead Sciences
- Report rights infringement
- published: 07 Feb 2017
- views: 96
Gilead Sciences, Inc: A Commitment To Innovation...
What's Gilead Sciences Doing With All That Cash?...
Gilead's 2017 Guidance Sank Shares To A New Bottom...
Gilead Sciences - Hot or Not...
Stock to Watch in ’17: Gilead Sciences...
Fireside Chat With John F. Milligan, PhD, Presiden...
What's Behind Gilead Sciences Drop In Hepatitis C ...
Gilead Sciences (GILD): Large-cap Biopharmaceutica...
Gilead Sciences - Hot or Not...
Gilead Sciences...
See more photos of Gilead Sciences
back
Philippines President Rodrigo Duterte jokes that soldiers can rape women under his martial law
Edit The Independent 27 May 2017
Philippines President Rodrigo Duterte has sought to reassure soldiers who might be accused of committing abuses under martial law and jokingly said that if any of them were to rape three women, he would personally claim responsibility for it ... He has, however, said he would not tolerate abuses. "If you go down, I go down....
back
Revealed: Jared Kushner 'wanted secret back channel' with Russia
Edit Irish Independent 27 May 2017
US President Donald Trump’s son-in-law and close adviser, Jared Kushner, had at least three previously undisclosed contacts with the Russian ambassador to the United States during and after the 2016 presidential campaign, seven current and former U.S. officials told Reuters. Those contacts included two phone calls between April and November last year, two of the sources said ... The White House did not respond to a request for comment ... ... ....
back
Family Outraged As Texas Teacher Names Student 'Most Likely To Become A Terrorist'
Edit WorldNews.com 26 May 2017
A middle school principal in Texas plans to launch an investigation after a 7th-grade student was named “most likely to become a terrorist” in a mock award ceremony, The Huffington Post reported Friday. “I was shocked ... “It was not a joke,” Lizeth was quoted as saying ... “Get fired, at least, or something,” Ena Hernandez said.“It doesn’t look good at all, especially coming from a teacher, a grown-up woman,” Hernandez said....
back
Former Speaker Boehner Calls Trump 'A Complete Disaster'
Edit WorldNews.com 26 May 2017
Former US House Speaker John Boehner has a strong message for President Donald Trump about his tenure as president. Aside from international affairs, Trump’s time in office thus far as been a ‘complete disaster,’ The Associated Press reported Friday ... "Everything else he's done (in office) has been a complete disaster ... The Senate has struggled to produce legislation that all in the GOP can back ... I smoke cigarettes. I golf....
back
Former U.S. national security adviser Brzezinski dies at 89
Edit Yahoo Daily News 27 May 2017
By Bill Trott. REUTERS - Former U.S. national security adviser Zbigniew Brzezinski, who established himself in the Carter administration as a hardliner on foreign policy, died on Friday, his family said. He was 89. Brzezinski's daughter Mika, a host on MSNBC's "Morning Joe" show, said on social media that her father died peacefully. She did not give the cause of his death ... That placed him at odds with two of Carter's closest advisers ... Bush....
Which Biotechs Benefit Most Under Trump's Tax Reform Vision?
Edit Investors Business Daily 27 May 2017
Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Biogen (BIIB) would benefit the most among biotechs under President Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20% ... That means Regeneron, Gilead and Biogen — all of which have guided to adjusted tax rates at or above 25% in 2017 — could see a serious boost in cash if Trump's proposal passes ... Gilead sees 25%-28%....
Gilead: Taking The Other Side Of The Bet
Edit Seeking Alpha 26 May 2017
Today I read an article by Giovanni DiMauro here on Seeking Alpha, in which he proposes buying call options on Gilead (NASDAQ.GILD) in order to get the chance for a very big return in a small time frame ... Gilead's shares are trading at $64 right now, after having hit a new 52 week low earlier this week ... Gilead's shares trade below $65, which means the options expire worthless, the money spent on the call options is completely lost....
Robin L. Washington of Gilead Sciences, Lifetime Achievement Award Winner
Edit Business Journal 26 May 2017
Long-range thinking to guide biotech innovator’s growth When it comes to the way companies spend money, Robin Washington has seen both ends of the spectrum in her career bridging high tech and biotech ... When she accepted the CFO job at biopharmaceutical company Gilead Sciences in 2008, however, Washington knew she was… ... ....
Gilead Sciences CFO named ‘Financial Woman of the Year’
Edit Business Journal 26 May 2017
The Financial Women of San Francisco selected Gilead Sciences Chief Financial Officer Robin Washington as its 2017 Financial Woman of the Year. Washington was also recognized this week as the recipient of the lifetime achievement award at the “2017 Bay Area CFO of the Year Awards,” a program conducted by Larkin Street Youth Services in partnership with the Business Times ... ....
Why Everyone's Talking About The Handmaid's Tale TV Show
Edit Sheerluxe 26 May 2017
When we got wind Margaret Atwood’s critically acclaimed novel, The Handmaid’s Tale, was being turned into a TV show, we knew it was going to be a hit ... And it’s well worth staying in for. What’s it about? ... It’s told from the perspective of Offred – played by Elisabeth Moss – a young woman who once had a husband and child but now works as a Handmaid in the American state of Gilead ... DISCLAIMER ... ....
Top of the Street: Petrofac, Experian, GlaxoSmithKline, Shell, Eni, Shire
Edit The Times of India 26 May 2017
A round-up of notable broker activity this morning from Europe's top-ranked* analysts. ... ** Petrofac ... ** Top-rated Berenberg analyst ups GlaxoSmithKline to "buy" pointing out that risks to GSK's HIV business, ViiV, from its competitor's Gilead newest product are skewed to the upside. Berenberg also notes that beyond this near-term risk, the market underappreciates the strength and breadth of GSK's diversified business ... ** Shire ... RELATED....
Influenza Vaccines and Drugs Market Growing at a CAGR of 10.24% During 2017 to 2022 Says a Report at ReportsnReports.com
Edit Market Watch 26 May 2017
Company Profiles are GlaxoSmithKline, Sanofi Pasteur, Inc., CSL Limited, Astrazeneca, Protein Sciences Corporation, Serum Institute of India PvtLtd., Emergent Biosolutions, Emergent Biosolutions, BioCryst Pharmaceuticals.Inc., Alvogen. Scope of the Report ... Other Report Highlights Market Dynamics - Trends, Drivers, Challenges Pipeline Analysis Company Analysis - Falvogen, Gilead Science and Bio Cryst. Related Reports. ... About Us. ... LinkedIn....
Gilead Is An Undervalued Dividend Machine
Edit Seeking Alpha 26 May 2017
Value Beyond the Price. It seems like there are many who are impatient with Gilead Sciences (NASDAQ.GILD). The company's dive in HCV revenues has caused total revenues and the stock price to drop, bringing out every Chicken Little in the coop. GILD's growth in non-HCV revenues has been all but forgotten, and the market has assigned a negative value to GILD's current HCV segment ... GILD data by YCharts ... Year. Repurchases ($Billion) ... 2015. 10 ... ....
Vascular Biogenics: An Under-The-Radar Oncology Play Near $6
Edit Seeking Alpha 26 May 2017
The only true wisdom is in knowing you know nothing. ―Socrates. The 53rd annual meeting of the American Society of Clinical Oncology known as the ASCO takes place in Chicago from June 2 to June 6 ... One of the companies that will have poster presentation is the following ... Company Overview.. Vascular Biogenics (NASDAQ ... Pipeline. ... A few months before that Gilead Sciences (NASDAQ.GILD) bought privately held Nimbus Apollo for up to $1.2 billion ... ....
Abivax: A Biotech With Blockbuster Potential
Edit Seeking Alpha 26 May 2017
Abivax (OTCPK.AAVXF) has developed a unique antiviral delivery platform using ingenious science to infiltrate cells and prevent replication of viruses ... There is another major potential spin off for Abivax 464 ... There is no lack of potential suitors for Abivax's technology, including Bristol-Myers Squibb Company (NYSE.BMY), ViiV Healthcare (Pfizer Inc.) (NYSE.PFE), GlaxoSmithKline plc (NYSE.GSK), Gilead Sciences Inc ... What Is Abivax? ... ... ....
How To Double Your Money On A 6% Up Move In Gilead Sciences
Edit Seeking Alpha 25 May 2017
Those investors looking for 100% gains may be able to cash in on a countertrend rally in Gilead Sciences (NASDAQ.GILD) with a move as small as 6% by July ... I have the right of ownership in Gilead until July 21st expiration at $65, the option's intrinsic value is worth zero. However, if Gilead trades to $68 before July 21 expiration, the option would be worth $3 plus any premium tied to it ... Where is Gilead going to trade from here?....
The Handmaid's Tale on TV: too disturbing even for Margaret Atwood
Edit The Guardian 25 May 2017
It’s a tiny, terrible moment on a spectrum of grander horrors, but it perfectly encapsulates the brutal reality of Gilead, the patriarchal theocracy that takes over America in Margaret Atwood’s 1985 novel and the new TV adaptation ... It is telling that The Handmaid’s Tale is sometimes miscategorised as science-fiction – we don’t like to consider it as a possibility....
‘The Handmaid’s Tale’ Postmortem: O-T Fagbenle Talks Luke’s Surprise Return
Edit Yahoo Daily News 25 May 2017
Luke is dead by the time Offred begins narrating her story in The Handmaid’s Tale, gunned down in a forest while his wife and daughter make a desperate, and ultimately futile, attempt to escape the grip of Gilead ... At the tail end of the sixth episode, Offred (Elisabeth Moss) learned from the representative of a visiting delegation from Mexico that Luke (O-T Fagbenle) avoided death at the hands of Gilead soldiers....
- 1
- 2
- 3
- 4
- 5
- Next page »
